PHARMACEUTICAL COMPOSITION FOR TREATING AVELLINO CORNEA DYSTROPHY COMPRISING AN ANTIBODY AGAINST TGF-BETA
    1.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR TREATING AVELLINO CORNEA DYSTROPHY COMPRISING AN ANTIBODY AGAINST TGF-BETA 审中-公开
    用于治疗包含TGF-βA抗体的AVELLINO CORNEA DYSTROPHY的药物组合物

    公开(公告)号:US20100322947A1

    公开(公告)日:2010-12-23

    申请号:US12858241

    申请日:2010-08-17

    IPC分类号: A61K39/395 A61P27/02

    CPC分类号: C07K16/22 A61K2039/505

    摘要: The present invention relates to a medicine for treating Avellino corneal dystrophy (ACD), and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy containing an antibody against TGF-β as an effective ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms of a patient with severe Avellino corneal dystrophy due to TGF-β induced by exposure to intense light, such as UV etc.

    摘要翻译: 本发明涉及一种用于治疗阿维拉氏角膜营养不良症(ACD)的药物,更具体地涉及用于治疗含有针对TGF-β1抗体的Avellino角膜营养不良的药物组合物。 作为有效成分。 本发明的药物组合物具有改善由于TGF-β受体导致的严重Avellino角膜营养不良患者症状的作用。 通过暴露于强光下,如紫外线等引起的

    DNA CHIP FOR DIAGNOSIS OF CORNEAL DYSTROPHY
    2.
    发明申请
    DNA CHIP FOR DIAGNOSIS OF CORNEAL DYSTROPHY 审中-公开
    用于诊断角膜晶状体的DNA芯片

    公开(公告)号:US20090305394A1

    公开(公告)日:2009-12-10

    申请号:US12160965

    申请日:2007-01-18

    IPC分类号: C07H21/04 C12M1/34

    CPC分类号: C12Q1/6883 C12Q2600/156

    摘要: The present invention relates to oligonucleotides for diagnosis of corneal dystrophy. More particularly, the present invention relates to oligonucleotides for detecting mutation of BIGH3 gene for diagnosis or corneal dystrophy including Avellino corneal dystrophy, which must be precisely diagnosed before vision correction surgery, and a DNA chip for diagnosis of corneal dystrophy, which has the oligonucleotides fixed thereon. According to the present invention, conventional microscopic diagnosis of corneal dystrophy can be replaced with a precise genetic method, which prevents a patient with corneal dystrophy from losing eyesight by eyesight correction surgery after erroneous diagnosis.

    摘要翻译: 本发明涉及用于诊断角膜营养不良的寡核苷酸。 更具体地,本发明涉及用于检测用于诊断或角膜营养不良的BIGH3基因的突变的寡核苷酸,其包括在视力矫正手术之前必须精确诊断的Avellino角膜营养不良,以及用于诊断角膜营养不良的DNA芯片,其具有固定的寡核苷酸 上。 根据本发明,可以用精确的遗传方法代替常规的角膜营养不良症的微观诊断,其可以防止角膜营养不良患者在错误诊断后通过视力矫正手术而失去视力。

    Agent for reduction of scar formation by using wound alkalinization
    5.
    发明授权
    Agent for reduction of scar formation by using wound alkalinization 失效
    通过使用伤口碱化来减少瘢痕形成的药剂

    公开(公告)号:US07255883B2

    公开(公告)日:2007-08-14

    申请号:US10312097

    申请日:2001-06-20

    IPC分类号: A01N59/00 A61K33/00

    CPC分类号: A61K33/00

    摘要: The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-β. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-β in a living organism.

    摘要翻译: 本发明涉及一种用于减少瘢痕形成的药剂,其通过用注射器将碳酸氢钠注入伤口的真皮组织来抑制瘢痕形成,以直接控制伤口部位的pH,即通过使伤口碱化以使TGF- 测试版 根据本发明,通过控制伤口愈合过程来减少瘢痕形成的药剂可以临床上立即应用于治疗泰乐菌瘢痕和瘢痕疙瘩等,对于治疗难治性纤维化疾病是有效的。 此外,本发明可以以许多方式广泛应用,作为可以控制活体中TGF-β的作用的简单工具。

    MARKER AND METHOD FOR CANCER DIAGNOSIS
    8.
    发明申请
    MARKER AND METHOD FOR CANCER DIAGNOSIS 审中-公开
    癌症诊断标记和方法

    公开(公告)号:US20090269750A1

    公开(公告)日:2009-10-29

    申请号:US12161005

    申请日:2007-01-18

    IPC分类号: C12Q1/68 C07H21/00 C40B40/06

    摘要: The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3′-terminal end of exon 2 region linked to the 5′-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression.

    摘要翻译: 本发明涉及使用粒细胞集落刺激因子(G-CSF)基因变异的诊断性癌症标志物及其制备方法,更具体地涉及诊断癌症和/或评价癌症状态的方法 使用具有与G-CSF基因的外显子4区的5'末端连接的外显子2的3'末端的寡核苷酸作为诊断性癌症标志物进行。 根据本发明,可以使用G-CSF基因表达的变化快速且准确地诊断癌症。